A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma
conventional surgery
Urogenital Diseases+13
+ Adenocarcinoma
+ Carcinoma
Treatment Study
Summary
Study start date: March 1, 1992
Actual date on which the first participant was enrolled.OBJECTIVES: Compare time to recurrence and survival of patients with single, low stage, nonmetastatic, well localized, and well delineated renal cell cancer treated with partial vs radical resection. Establish the side effects of kidney-sparing tumor resection in terms of morbidity and mortality in these patients. Study the relationship between tumor size, histologic grade, histologic type, and the extent of local control following partial resection. Determine which prognostic factors are important in selecting candidates for conservative surgery. OUTLINE: This is a randomized, multicenter study. Patients are randomized to undergo radical nephrectomy and limited lymphadenectomy (arm I) or conservative surgery (arm II). Patients are followed every 3 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, then annually thereafter. PROJECTED ACCRUAL: A total of 1300 patients will be accrued for this study over 8 years.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
DISEASE CHARACTERISTICS: Single renal T1-2 tumor suspicious for adenocarcinoma that meets the following requirements: Solitary tumor on CT scan Maximum diameter 5 cm Located such that negative resection margins are assured N0, M0, i.e., no nodal involvement or distant metastases No invasion of renal pelvis, calices, or perirenal fat as determined by CT scan or intravenous urography Normal contralateral kidney present No von Hippel-Lindau disease PATIENT CHARACTERISTICS: Age: Any age Performance status: WHO 0-2 Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No second malignancy except adequately treated nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 2 locations
Sunnybrook and Women's College Health Sciences Centre
North York, CanadaOpen Sunnybrook and Women's College Health Sciences Centre in Google MapsMcGill University
Montreal, Canada